SPCs: The semantics of protection

Combination therapies (those containing multiple active ingredients) are becoming increasingly prevalent due to factors such as public health policy, improved therapeutic effects of combining drugs, and the need to reduce the pill burden on patients.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Fed Circ overturns PTAB decision in $83.4m DNA case

26 January 2026 The court found the board applied the wrong legal standard when evaluating Guardant Health’s obviousness challenge to a University of Washington DNA sequencing patent.

Americas

AI is transforming top 100 innovators, shows index

23 January 2026 Just one pharma company is recognised in a report that lists the most world's most inventive countries and companies.

Americas

Novartis win blocks generics relitigating $7.8bn heart drug patent

22 January 2026 A district court judge shuts down a Novartis rival from reopening validity and infringement arguments over an Entresto patent.